23 results on '"Overby, Anna K."'
Search Results
2. SARS-CoV-2 hijacks fragile X mental retardation proteins for efficient infection
- Author
-
Garvanska, Dimitriya, primary, Alvarado, Rojelio E, additional, Mundt, Filip, additional, Nilsson, Emma, additional, Duel, Josephine, additional, Coscia, Fabian, additional, Lindqvist, Richard, additional, Lokugamage, Kumari, additional, Johnson, Bryan, additional, Plante, Jessica A, additional, Morris, Dorothea R., additional, Vu, Michelle N, additional, Estes, Leah, additional, McLeland, Alyssa, additional, Walker, Jordyn, additional, Crocquet-Valdes, Patricia, additional, Lopez-Mendez, Blanca, additional, Plante, Kenneth, additional, Walker, David H., additional, Weisser, Melanie B, additional, Overby, Anna K, additional, Mann, Matthias, additional, Menachery, Vineet D, additional, and Nilsson, Jakob, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Correlation of Severity of Human Tick-Borne Encephalitis Virus Disease and Pathogenicity in Mice
- Author
-
Kurhade, Chaitanya, Schreier, Sarah, Lee, Yi-Ping, Zegenhagen, Loreen, Hjertqvist, Marika, Dobler, Gerhard, Kroger, Andrea, and Overby, Anna K.
- Subjects
Contamination ,Health aspects ,Tick-borne encephalitis -- Health aspects ,Bites (Injuries) -- Health aspects ,Disease transmission -- Health aspects ,Food contamination -- Health aspects - Abstract
Tick-borne encephalitis (TBE) is an emerging arthropod-borne viral (arboviral) disease in Europe and Asia characterized by severe central nervous system (CNS) disease in humans. New areas of endemicity and increased [...]
- Published
- 2018
- Full Text
- View/download PDF
4. Large-scale phage-based screening reveals extensive pan-viral mimicry of host short linear motifs
- Author
-
Mihalič, Filip, Simonetti, Leandro, Giudice, Girolamo, Rubin Sander, Marie, Lindqvist, Richard, Peters, Marie Berit Akpiroro, Benz, Caroline, Kassa, Eszter, Badgujar, Dilip, Inturi, Raviteja, Ali, Muhammad, Krystkowiak, Izabella, Sayadi, Ahmed, Andersson, Eva, Aronsson, Hanna, Söderberg, Ola, Dobritzsch, Doreen, Petsalaki, Evangelia, Overby, Anna K., Jemth, Per, Davey, Norman E., Ivarsson, Ylva, Mihalič, Filip, Simonetti, Leandro, Giudice, Girolamo, Rubin Sander, Marie, Lindqvist, Richard, Peters, Marie Berit Akpiroro, Benz, Caroline, Kassa, Eszter, Badgujar, Dilip, Inturi, Raviteja, Ali, Muhammad, Krystkowiak, Izabella, Sayadi, Ahmed, Andersson, Eva, Aronsson, Hanna, Söderberg, Ola, Dobritzsch, Doreen, Petsalaki, Evangelia, Overby, Anna K., Jemth, Per, Davey, Norman E., and Ivarsson, Ylva
- Abstract
Viruses mimic host short linear motifs (SLiMs) to hijack and deregulate cellular functions. Studies of motif-mediated interactions therefore provide insight into virus-host dependencies, and reveal targets for therapeutic intervention. Here, we describe the pan-viral discovery of 1712 SLiM-based virus-host interactions using a phage peptidome tiling the intrinsically disordered protein regions of 229 RNA viruses. We find mimicry of host SLiMs to be a ubiquitous viral strategy, reveal novel host proteins hijacked by viruses, and identify cellular pathways frequently deregulated by viral motif mimicry. Using structural and biophysical analyses, we show that viral mimicry-based interactions have similar binding strength and bound conformations as endogenous interactions. Finally, we establish polyadenylate-binding protein 1 as a potential target for broad-spectrum antiviral agent development. Our platform enables rapid discovery of mechanisms of viral interference and the identification of potential therapeutic targets which can aid in combating future epidemics and pandemics.
- Published
- 2023
- Full Text
- View/download PDF
5. Serine Protease Inhibitors Restrict Host Susceptibility to SARS-CoV-2 Infections
- Author
-
Rosendal, Ebba, Mihai, Ionut Sebastian, Becker, Miriam, Das, Debojyoti, Frangsmyr, Lars, Persson, B. David, Rankin, Gregory D., Groning, Remigius, Trygg, Johan, Forsell, Mattias, Ankarklev, Johan, Blomberg, Anders, Henriksson, Johan, Overby, Anna K., Lenman, Annasara, Rosendal, Ebba, Mihai, Ionut Sebastian, Becker, Miriam, Das, Debojyoti, Frangsmyr, Lars, Persson, B. David, Rankin, Gregory D., Groning, Remigius, Trygg, Johan, Forsell, Mattias, Ankarklev, Johan, Blomberg, Anders, Henriksson, Johan, Overby, Anna K., and Lenman, Annasara
- Abstract
Identification of host factors affecting individual SARS-CoV-2 susceptibility will provide a better understanding of the large variations in disease severity and will identify potential factors that can be used, or targeted, in antiviral drug development. With the use of an advanced lung cell model established from several human donors, we identified cellular protease inhibitors, serpins, as host factors that restrict SARS-CoV-2 infection. The coronavirus disease 2019, COVID-19, is a complex disease with a wide range of symptoms from asymptomatic infections to severe acute respiratory syndrome with lethal outcome. Individual factors such as age, sex, and comorbidities increase the risk for severe infections, but other aspects, such as genetic variations, are also likely to affect the susceptibility to SARS-CoV-2 infection and disease severity. Here, we used a human 3D lung cell model based on primary cells derived from multiple donors to identity host factors that regulate SARS-CoV-2 infection. With a transcriptomics-based approach, we found that less susceptible donors show a higher expression level of serine protease inhibitors SERPINA1, SERPINE1, and SERPINE2, identifying variation in cellular serpin levels as restricting host factors for SARS-CoV-2 infection. We pinpoint their antiviral mechanism of action to inhibition of the cellular serine protease, TMPRSS2, thereby preventing cleavage of the viral spike protein and TMPRSS2-mediated entry into the target cells. By means of single-cell RNA sequencing, we further locate the expression of the individual serpins to basal, ciliated, club, and goblet cells. Our results add to the importance of genetic variations as determinants for SARS-CoV-2 susceptibility and suggest that genetic deficiencies of cellular serpins might represent risk factors for severe COVID-19. Our study further highlights TMPRSS2 as a promising target for antiviral intervention and opens the door for the usage of locally administered serpins as
- Published
- 2022
- Full Text
- View/download PDF
6. Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re : Karin Welen, Ebba Rosendal, Magnus Gisslen, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285-93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients
- Author
-
Welen, Karin, Rosendal, Ebba, Freyhult, Eva, Oh, William K., Gisslen, Magnus, Ahlm, Clas, Connolly, Anne-Marie Fors, Overby, Anna K., Josefsson, Andreas, Welen, Karin, Rosendal, Ebba, Freyhult, Eva, Oh, William K., Gisslen, Magnus, Ahlm, Clas, Connolly, Anne-Marie Fors, Overby, Anna K., and Josefsson, Andreas
- Published
- 2022
- Full Text
- View/download PDF
7. Re: Chen Dong, Sung-Lang Chen, and Wen-Wei Sung's Letter to the Editor re: Karin Welen, Ebba Rosendal, Magnus Gisslen, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285-93
- Author
-
Welen, Karin, Rosendal, Ebba, Freyhult, Eva, Connolly, Anne-Marie Fors, Overby, Anna K., Josefsson, Andreas, Welen, Karin, Rosendal, Ebba, Freyhult, Eva, Connolly, Anne-Marie Fors, Overby, Anna K., and Josefsson, Andreas
- Published
- 2022
- Full Text
- View/download PDF
8. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome : No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
- Author
-
Welen, Karin, Rosendal, Ebba, Gisslen, Magnus, Lenman, Annasara, Freyhult, Eva, Fonseca-Rodriguez, Osvaldo, Bremell, Daniel, Stranne, Johan, Balkhed, Ase Ostholm, Niward, Katarina, Repo, Johanna, Robinsson, David, Henningsson, Anna J., Styrke, Johan, Angelin, Martin, Lindquist, Elisabeth, Allard, Annika, Becker, Miriam, Rudolfsson, Stina, Buckland, Robert, Carlsson, Camilla Thellenberg, Bjartell, Anders, Nilsson, Anna C., Ahlm, Clas, Connolly, Anne-Marie Fors, Overby, Anna K., Josefsson, Andreas, Welen, Karin, Rosendal, Ebba, Gisslen, Magnus, Lenman, Annasara, Freyhult, Eva, Fonseca-Rodriguez, Osvaldo, Bremell, Daniel, Stranne, Johan, Balkhed, Ase Ostholm, Niward, Katarina, Repo, Johanna, Robinsson, David, Henningsson, Anna J., Styrke, Johan, Angelin, Martin, Lindquist, Elisabeth, Allard, Annika, Becker, Miriam, Rudolfsson, Stina, Buckland, Robert, Carlsson, Camilla Thellenberg, Bjartell, Anders, Nilsson, Anna C., Ahlm, Clas, Connolly, Anne-Marie Fors, Overby, Anna K., and Josefsson, Andreas
- Abstract
Background: Men are more severely affected by COVID-19. Testosterone may influence SARS-CoV-2 infection and the immune response. Objective: To clinically, epidemiologically, and experimentally evaluate the effect of antiandrogens on SARS-CoV-2 infection. Designs, settings, and participants: A randomized phase 2 clinical trial (COVIDENZA) enrolled 42 hospitalized COVID-19 patients before safety evaluation. We also conducted a population-based retrospective study of 7894 SARS-CoV-2-positive prostate cancer patients and an experimental study using an air-liquid interface three-dimensional culture model of primary lung cells. Intervention: In COVIDENZA, patients were randomized 2:1 to 5 d of enzalutamide or standard of care. Outcome measurements: The primary outcomes in COVIDENZA were the time to mechanical ventilation or discharge from hospital. The population-based study investigated risk of hospitalization, intensive care, and death from COVID-19 after androgen inhibition. Results and limitations: Enzalutamide-treated patients required longer hospitalization (hazard ratio [HR] for discharge from hospital 0.43, 95% confidence interval [CI] 0.20-0.93) and the trial was terminated early. In the epidemiological study, no preventive effects were observed. The frail population of patients treated with androgen deprivation therapy (ADT) in combination with abiraterone acetate or enzalutamide had a higher risk of dying from COVID-19 (HR 2.51, 95% CI 1.52-4.16). In vitro data showed no effect of enzalutamide on virus replication. The epidemiological study has limitations that include residual confounders. Conclusions: The results do not support a therapeutic effect of enzalutamide or preventive effects of bicalutamide or ADT in COVID-19. Thus, these antiandrogens should not be used for hospitalized COVID-19 patients or as prevention for COVID-19. Further research on these therapeutics in this setting are not warranted. Patient summary: We studied whether inhibition of testost
- Published
- 2022
- Full Text
- View/download PDF
9. A Syntenin Inhibitor Blocks Endosomal Entry of SARS-CoV-2 and a Panel of RNA Viruses
- Author
-
Lindqvist, Richard, Benz, Caroline, Sereikaite, Vita, Maassen, Lars, Laursen, Louise, Jemth, Per, Stromgaard, Kristian, Ivarsson, Ylva, Overby, Anna K., Lindqvist, Richard, Benz, Caroline, Sereikaite, Vita, Maassen, Lars, Laursen, Louise, Jemth, Per, Stromgaard, Kristian, Ivarsson, Ylva, and Overby, Anna K.
- Abstract
Viruses are dependent on host factors in order to efficiently establish an infection and replicate. Targeting the interactions of such host factors provides an attractive strategy to develop novel antivirals. Syntenin is a protein known to regulate the architecture of cellular membranes by its involvement in protein trafficking and has previously been shown to be important for human papilloma virus (HPV) infection. Here, we show that a highly potent and metabolically stable peptide inhibitor that binds to the PDZ1 domain of syntenin inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by blocking the endosomal entry of the virus. Furthermore, we found that the inhibitor also hampered chikungunya infection and strongly reduced flavivirus infection, which is completely dependent on receptor-mediated endocytosis for their entry. In conclusion, we have identified a novel broad spectrum antiviral inhibitor that efficiently targets a broad range of RNA viruses.
- Published
- 2022
10. Detection of asymptomatic SARS-CoV-2 exposed individuals by a sensitive S-based ELISA
- Author
-
Rosendal, Ebba, Wigren, Julia, Groening, Remigius, Yongdae, Kwon, Nilsson, Emma, Sharma, Atin, espaillat, akbar, Hanke, Leo, Thunberg, Therese, McInerney, Gerald, Puhar, Andrea, Cava, Felipe, Karlsson Hedestam, Gunilla B, Monsen, Tor, Elgh, Fredrik, Blomkvist, Bert, Marklund, Ingrid, Ahlm, Clas, Evander, Magnus, Normark, Johan, Johansson, Anders, Overby, Anna K, and Forsell, Mattias
- Subjects
viruses ,virus diseases ,Article - Abstract
The current SARS-CoV-2 pandemic has highlighted a need for easy and safe blood sampling in combination with accurate serological methodology. Venipuncture is usually performed by trained staff at health care centers. Long travel distances may introduce a bias of testing towards relatively large communities with close access to health care centers. Rural regions may thus be overlooked. Here, we demonstrate a sensitive method to measure antibodies to the S-protein of SARS-CoV-2. We adapted and optimized this assay for clinical use together with capillary blood sampling to meet the geographical challenges of serosurveillance. Finally, we tested remote at-home capillary blood sampling together with centralized assessment of S-specific IgG in a rural region of northern Scandinavia that encompasses 55,185 sq kilometers. We conclude that serological assessment from capillary blood sampling gives comparable results as analysis of venous blood. Importantly, at-home sampling enabled citizens living in remote rural areas access to centralized and sensitive laboratory antibody tests.
- Published
- 2020
11. COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19) : a structured summary of a study protocol for a randomised controlled trial
- Author
-
Welen, Karin, Overby, Anna K., Ahlm, Clas, Freyhult, Eva, Robinsson, David, Henningsson, Anna Jonsson, Stranne, Johan, Bremell, Daniel, Angelin, Martin, Lindquist, Elisabeth, Buckland, Robert, Carlsson, Camilla Thellenberg, Pauksens, Karlis, Bill-Axelson, Anna, Akre, Olof, Ryden, Cecilia, Wagenius, Magnus, Bjartell, Anders, Nilsson, Anna C., Styrke, Johan, Repo, Johanna, Balkhed, Ase Osholm, Niward, Katarina, Gisslen, Magnus, Josefsson, Andreas, Welen, Karin, Overby, Anna K., Ahlm, Clas, Freyhult, Eva, Robinsson, David, Henningsson, Anna Jonsson, Stranne, Johan, Bremell, Daniel, Angelin, Martin, Lindquist, Elisabeth, Buckland, Robert, Carlsson, Camilla Thellenberg, Pauksens, Karlis, Bill-Axelson, Anna, Akre, Olof, Ryden, Cecilia, Wagenius, Magnus, Bjartell, Anders, Nilsson, Anna C., Styrke, Johan, Repo, Johanna, Balkhed, Ase Osholm, Niward, Katarina, Gisslen, Magnus, and Josefsson, Andreas
- Abstract
Objectives: The main goal of the COVIDENZA trial is to evaluate if inhibition of testosterone signalling by enzalutamide can improve the outcome of patients hospitalised for COVID-19. The hypothesis is based on the observation that the majority of patients in need of intensive care are male, and the connection between androgen receptor signalling and expression of TMPRSS2, an enzyme important for SARS-CoV-2 host cell internalization. Trial design: Hospitalised COVID-19 patients will be randomised (2:1) to enzalutamide plus standard of care vs. standard of care designed to identify superiority. Participants: Included participants, men or women above 50 years of age, must be hospitalised for PCR confirmed COVID-19 symptoms and not in need of immediate mechanical ventilation. Major exclusion criteria are breast-feeding or pregnant women, hormonal treatment for prostate or breast cancer, treatment with immunosuppressive drugs, current symptomatic unstable cardiovascular disease (see Additional file 1 for further details). The trial is registered at Umea University Hospital, Region Vasterbotten, Sweden and 8 hospitals are approved for inclusion in Sweden. Intervention and comparator: Patients randomised to the treatment arm will be treated orally with 160 mg (4x40 mg) enzalutamide (Xtandi (R)) daily, for five consecutive days. The study is not placebo controlled. The comparator is standard of care treatment for patients hospitalised with COVID-19. Main outcomes: The primary endpoints of the study are (time to) need of mechanical ventilation or discharge from hospital as assessed by a clinical 7-point ordinal scale (up to 30 days after inclusion). Randomisation: Randomisation was stratified by center and sex. Each strata was randomized separately with block size six with a 2:1 allocation ratio (enzalutamide + "standard of care": "standard of care"). The randomisation list, with consecutive subject numbers, was generated by an independent statistician using the PROC PLAN p
- Published
- 2021
- Full Text
- View/download PDF
12. Human Tick-Borne Encephalitis and Characterization of Virus from Biting Tick
- Author
-
Henningsson, Anna, Lindqvist, Richard, Norberg, Peter, Lindblom, Pontus, Roth, Anette, Forsberg, Pia, Bergstrom, Tomas, Overby, Anna K., Lindgren, Per-Eric, Henningsson, Anna, Lindqvist, Richard, Norberg, Peter, Lindblom, Pontus, Roth, Anette, Forsberg, Pia, Bergstrom, Tomas, Overby, Anna K., and Lindgren, Per-Eric
- Abstract
We report a case of human tick-borne encephalitis (TBE) in which the TBE virus was isolated from the biting tick. Viral growth and sequence were characterized and compared with those of a reference strain. Virus isolation from ticks from patients with TBE may offer a new approach for studies of epidemiology and pathogenicity., Funding Agencies|Swedish Research Council; Laboratory for Molecular Infection Medicine Sweden; Medical Research Council of South-eastern Sweden; ScandTick and ScandTick Innovation; 2 European Union Interreg projects in the Oresund-Kattegatt-Skagerrak region
- Published
- 2016
- Full Text
- View/download PDF
13. Tick-borne encephalitis virus sequenced directly from questing and blood-feeding ticks reveals quasispecies variance.
- Author
-
Asghar, Naveed, Lindblom, Pontus, Melik, Wessam, Lindqvist, Richard, Haglund, Mats, Forsberg, Pia, Overby, Anna K, Andreassen, Ashild, Lindgren, Per-Eric, Johansson, Magnus, Asghar, Naveed, Lindblom, Pontus, Melik, Wessam, Lindqvist, Richard, Haglund, Mats, Forsberg, Pia, Overby, Anna K, Andreassen, Ashild, Lindgren, Per-Eric, and Johansson, Magnus
- Abstract
The increased distribution of the tick-borne encephalitis virus (TBEV) in Scandinavia highlights the importance of characterizing novel sequences within the natural foci. In this study, two TBEV strains: the Norwegian Mandal 2009 (questing nymphs pool) and the Swedish Saringe 2009 (blood-fed nymph) were sequenced and phylogenetically characterized. Interestingly, the sequence of Mandal 2009 revealed the shorter form of the TBEV genome, similar to the highly virulent Hypr strain, within the 3' non-coding region (3'NCR). A different genomic structure was found in the 3'NCR of Saringe 2009, as in-depth analysis demonstrated TBEV variants with different lengths within the poly(A) tract. This shows that TBEV quasispecies exists in nature and indicates a putative shift in the quasispecies pool when the virus switches between invertebrate and vertebrate environments. This prompted us to further sequence and analyze the 3'NCRs of additional Scandinavian TBEV strains and control strains, Hypr and Neudoerfl. Toro 2003 and Habo 2011 contained mainly a short (A)3C(A)6 poly(A) tract. A similar pattern was observed for the human TBEV isolates 1993/783 and 1991/4944; however, one clone of 1991/4944 contained an (A)3C(A)11 poly(A) sequence, demonstrating that quasispecies with longer poly(A) could be present in human isolates. Neudoerfl has previously been reported to contain a poly(A) region, but to our surprise the re-sequenced genome contained two major quasispecies variants, both lacking the poly(A) tract. We speculate that the observed differences are important factors for the understanding of virulence, spread, and control of the TBEV.
- Published
- 2014
- Full Text
- View/download PDF
14. SARS-CoV-2 hijacks fragile X mental retardation proteins for efficient infection.
- Author
-
Garvanska DH, Alvarado RE, Mundt FO, Nilsson E, Duel JK, Coscia F, Lindqvist R, Lokugamage K, Johnson BA, Plante JA, Morris DR, Vu MN, Estes LK, McLeland AM, Walker J, Crocquet-Valdes PA, Mendez BL, Plante KS, Walker DH, Weisser MB, Overby AK, Mann M, Menachery VD, and Nilsson J
- Abstract
Viruses interact with numerous host factors to facilitate viral replication and to dampen antiviral defense mechanisms. We currently have a limited mechanistic understanding of how SARS-CoV-2 binds host factors and the functional role of these interactions. Here, we uncover a novel interaction between the viral NSP3 protein and the fragile X mental retardation proteins (FMRPs: FMR1 and FXR1-2). SARS-CoV-2 NSP3 mutant viruses preventing FMRP binding have attenuated replication in vitro and have delayed disease onset in vivo . We show that a unique peptide motif in NSP3 binds directly to the two central KH domains of FMRPs and that this interaction is disrupted by the I304N mutation found in a patient with fragile X syndrome. NSP3 binding to FMRPs disrupts their interaction with the stress granule component UBAP2L through direct competition with a peptide motif in UBAP2L to prevent FMRP incorporation into stress granules. Collectively, our results provide novel insight into how SARS-CoV-2 hijacks host cell proteins for efficient infection and provides molecular insight to the possible underlying molecular defects in fragile X syndrome., Competing Interests: Competing Interest Statement: VDM has filed a patent on the reverse genetic system and reporter SARS-CoV-2. Other authors declare no competing interests.
- Published
- 2023
- Full Text
- View/download PDF
15. Hiding from intracellular pattern recognition receptors, a passive strategy of flavivirus immune evasion.
- Author
-
Overby AK and Weber F
- Subjects
- Cytoplasmic Vesicles virology, Humans, Models, Biological, RNA, Double-Stranded immunology, RNA, Viral immunology, Encephalitis Viruses, Tick-Borne immunology, Encephalitis Viruses, Tick-Borne pathogenicity, Immune Evasion, Interferon Type I immunology, Receptors, Pattern Recognition immunology
- Abstract
Tick-borne encephalitis virus (TBEV) is a medically important flavivirus in Europe and Asia, causing meningitis and encephalitis in thousands of people annually. Despite its relevance for public health, the interaction of TBEV with the type I interferon (IFN) system is poorly characterized. Induction of these antiviral cytokines is normally triggered by cytoplasmic recognition of viral signature molecules such as double-stranded (ds) RNA. In a recent paper, we showed that TBEV infection leads to formation of intracellular membrane vesicles which protect the viral dsRNA from cellular recognition. This delays the onset of antiviral IFN production sufficiently enough for an unhindered release of progeny viruses over 24 h. Thus, TBEV has evolved a stealth strategy to outrun the antiviral IFN response.
- Published
- 2011
- Full Text
- View/download PDF
16. Tick-borne encephalitis virus delays interferon induction and hides its double-stranded RNA in intracellular membrane vesicles.
- Author
-
Overby AK, Popov VL, Niedrig M, and Weber F
- Subjects
- Animals, Cell Line, Chlorocebus aethiops, Cricetinae, Cytoplasmic Vesicles genetics, Cytoplasmic Vesicles immunology, Encephalitis Viruses, Tick-Borne genetics, Encephalitis, Tick-Borne immunology, Encephalitis, Tick-Borne virology, Humans, Interferon-alpha immunology, Interferon-beta immunology, Mice, RNA, Double-Stranded metabolism, RNA, Viral metabolism, Transcriptional Activation, Vero Cells, Virus Replication, Cytoplasmic Vesicles virology, Encephalitis Viruses, Tick-Borne physiology, Encephalitis, Tick-Borne genetics, Interferon-alpha genetics, Interferon-beta genetics, RNA, Double-Stranded genetics, RNA, Viral genetics
- Abstract
Tick-borne encephalitis virus (TBEV) (family Flaviviridae, genus Flavivirus) accounts for approximately 10,000 annual cases of severe encephalitis in Europe and Asia. Here, we investigated the induction of the antiviral type I interferons (IFNs) (alpha/beta IFN [IFN-alpha/beta]) by TBEV. Using strains Neudörfl, Hypr, and Absettarov, we demonstrate that levels of IFN-beta transcripts and viral RNA are strictly correlated. Moreover, IFN induction by TBEV was dependent on the transcription factor IFN regulatory factor 3 (IRF-3). However, even strain Hypr, which displayed the strongest IFN-inducing activity and the highest RNA levels, substantially delayed the activation of IRF-3. As a consequence, TBEV can keep the level of IFN transcripts below the threshold value that would permit the release of IFN by the cell. Only after 24 h of infection have cells accumulated sufficient IFN transcripts to produce detectable amounts of secreted IFNs. The delay in IFN induction appears not to be caused by a specific viral protein, since the individual expressions of TBEV C, E, NS2A, NS2B, NS3, NS4A, NS4B, NS5, and NS2B-NS3, as well as TBEV infection itself, had no apparent influence on specific IFN-beta induction. We noted, however, that viral double-stranded RNA (dsRNA), an important trigger of the IFN response, is immunodetectable only inside intracellular membrane compartments. Nonetheless, the dependency of IFN induction on IFN promoter stimulator 1 (IPS-1) as well as the phosphorylation of the alpha subunit of eukaryotic initiation factor 2 (eIF2alpha) suggest the cytoplasmic exposure of some viral dsRNA late in infection. Using ultrathin-section electron microscopy, we demonstrate that, similar to other flaviviruses, TBEV rearranges intracellular membranes. Virus particles and membrane-connected vesicles (which most likely represent sites of virus RNA synthesis) were observed inside the endoplasmic reticulum. Thus, apparently, TBEV rearranges internal cell membranes to provide a compartment for its dsRNA, which is largely inaccessible for detection by cytoplasmic pathogen receptors. This delays the onset of IFN induction sufficiently to give progeny particle production a head start of approximately 24 h.
- Published
- 2010
- Full Text
- View/download PDF
17. Entry of bunyaviruses into mammalian cells.
- Author
-
Lozach PY, Mancini R, Bitto D, Meier R, Oestereich L, Overby AK, Pettersson RF, and Helenius A
- Subjects
- Animals, Cell Line, Endocytosis, Endosomes chemistry, Endosomes virology, Humans, Hydrogen-Ion Concentration, Lysosomal-Associated Membrane Protein 1 analysis, Microscopy, Electron, Transmission, Microscopy, Fluorescence, rab GTP-Binding Proteins analysis, rab5 GTP-Binding Proteins analysis, rab7 GTP-Binding Proteins, Uukuniemi virus physiology, Virus Internalization
- Abstract
The Bunyaviridae constitute a large family of enveloped animal viruses, many members of which cause serious diseases. However, early bunyavirus-host cell interactions and entry mechanisms remain largely uncharacterized. Investigating Uukuniemi virus, a bunyavirus of the genus Phlebovirus, we found that virus attachment to the cell surface was specific but inefficient, with 25% of bound viruses being endocytosed within 10 min, mainly via noncoated vesicles. The viruses entered Rab5a+ early endosomes and, subsequently, Rab7a+ and LAMP-1+ late endosomes. Acid-activated penetration, occurring 20-40 min after internalization, required maturation of early to late endosomes. The pH threshold for viral membrane fusion was 5.4, and entry was sensitive to temperatures below 25 degrees C. Together, our results indicate that Uukuniemi virus penetrates host cells by acid-activated membrane fusion from late endosomal compartments. This study also highlights the importance of the degradative branch of the endocytic pathway in facilitating entry of late-penetrating viruses., (Copyright (c) 2010 Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
18. NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase.
- Author
-
Habjan M, Pichlmair A, Elliott RM, Overby AK, Glatter T, Gstaiger M, Superti-Furga G, Unger H, and Weber F
- Subjects
- Animals, Antiviral Agents pharmacology, Cells, Cultured, Chlorocebus aethiops, Humans, Interferons pharmacology, Mice, Mice, Knockout, Phenotype, Proteasome Endopeptidase Complex metabolism, RNA, Double-Stranded, Rift Valley fever virus drug effects, Rift Valley fever virus genetics, Substrate Specificity, Viral Nonstructural Proteins genetics, Virus Replication drug effects, eIF-2 Kinase deficiency, eIF-2 Kinase genetics, Rift Valley fever virus metabolism, Viral Nonstructural Proteins metabolism, eIF-2 Kinase metabolism
- Abstract
Rift Valley fever virus (RVFV) continues to cause large outbreaks of acute febrile and often fatal illness among humans and domesticated animals in Africa, Saudi Arabia, and Yemen. The high pathogenicity of this bunyavirus is mainly due to the viral protein NSs, which was shown to prevent transcriptional induction of the antivirally active type I interferons (alpha/beta interferon [IFN-alpha/beta]). Viruses lacking the NSs gene induce synthesis of IFNs and are therefore attenuated, whereas the noninducing wild-type RVFV strains can only be inhibited by pretreatment with IFN. We demonstrate here in vitro and in vivo that a substantial part of the antiviral activity of IFN against RVFV is due to a double-stranded RNA-dependent protein kinase (PKR). PKR-mediated virus inhibition, however, was much more pronounced for the strain Clone 13 with NSs deleted than for the NSs-expressing strain ZH548. In vivo, Clone 13 was nonpathogenic for wild-type (wt) mice but could regain pathogenicity if mice lacked the PKR gene. ZH548, in contrast, killed both wt and PKR knockout mice indiscriminately. ZH548 was largely resistant to the antiviral properties of PKR because RVFV NSs triggered the specific degradation of PKR via the proteasome. The NSs proteins of the related but less virulent sandfly fever Sicilian virus and La Crosse virus, in contrast, had no such anti-PKR activity despite being efficient suppressors of IFN induction. Our data suggest that RVFV NSs has gained an additional anti-IFN function that may explain the extraordinary pathogenicity of this virus.
- Published
- 2009
- Full Text
- View/download PDF
19. Electron cryo-microscopy and single-particle averaging of Rift Valley fever virus: evidence for GN-GC glycoprotein heterodimers.
- Author
-
Huiskonen JT, Overby AK, Weber F, and Grünewald K
- Subjects
- Cryoelectron Microscopy, Imaging, Three-Dimensional, Dimerization, Rift Valley fever virus ultrastructure, Viral Envelope Proteins metabolism, Viral Envelope Proteins ultrastructure
- Abstract
Rift Valley fever virus (RVFV) is a member of the genus Phlebovirus within the family Bunyaviridae. It is a mosquito-borne zoonotic agent that can cause hemorrhagic fever in humans. The enveloped RVFV virions are known to be covered by capsomers of the glycoproteins G(N) and G(C), organized on a T=12 icosahedral lattice. However, the structural units forming the RVFV capsomers have not been determined. Conflicting biochemical results for another phlebovirus (Uukuniemi virus) have indicated the existence of either G(N) and G(C) homodimers or G(N)-G(C) heterodimers in virions. Here, we have studied the structure of RVFV using electron cryo-microscopy combined with three-dimensional reconstruction and single-particle averaging. The reconstruction at 2.2-nm resolution revealed the organization of the glycoprotein shell, the lipid bilayer, and a layer of ribonucleoprotein (RNP). Five- and six-coordinated capsomers are formed by the same basic structural unit. Molecular-mass measurements suggest a G(N)-G(C) heterodimer as the most likely candidate for this structural unit. Both leaflets of the lipid bilayer were discernible, and the glycoprotein transmembrane densities were seen to modulate the curvature of the lipid bilayer. RNP densities were situated directly underneath the transmembrane densities, suggesting an interaction between the glycoprotein cytoplasmic tails and the RNPs. The success of the single-particle averaging approach taken in this study suggests that it is applicable in the study of other phleboviruses, as well, enabling higher-resolution description of these medically important pathogens.
- Published
- 2009
- Full Text
- View/download PDF
20. Efficient production of Rift Valley fever virus-like particles: The antiviral protein MxA can inhibit primary transcription of bunyaviruses.
- Author
-
Habjan M, Penski N, Wagner V, Spiegel M, Overby AK, Kochs G, Huiskonen JT, and Weber F
- Subjects
- Animals, Antibodies, Monoclonal, Antiviral Agents metabolism, Cell Line, Chlorocebus aethiops, GTP-Binding Proteins pharmacology, Gene Expression Regulation, Viral drug effects, Humans, Mice, Myxovirus Resistance Proteins, Recombinant Proteins genetics, Vero Cells, Virology methods, Recombinant Proteins metabolism, Rift Valley fever virus genetics, Rift Valley fever virus metabolism, Virion metabolism
- Abstract
Rift Valley fever virus (RVFV) is a highly pathogenic member of the family Bunyaviridae that needs to be handled under biosafety level (BSL) 3 conditions. Here, we describe reverse genetics systems to measure RVFV polymerase activity in mammalian cells and to generate virus-like particles (VLPs). Recombinant polymerase (L) and nucleocapsid protein (N), expressed together with a minireplicon RNA, formed transcriptionally active nucleocapsids. These could be packaged into VLPs by additional expression of viral glycoproteins. The VLPs resembled authentic virus particles and were able to infect new cells. After infection, VLP-associated nucleocapsids autonomously performed primary transcription, and co-expression of L and N in VLP-infected cells allowed subsequent replication and secondary transcription. Bunyaviruses are potently inhibited by a human interferon-induced protein, MxA. However, the affected step in the infection cycle is not entirely characterized. Using the VLP system, we demonstrate that MxA inhibits both primary and secondary transcriptions of RVFV. A set of infection assays distinguishing between virus attachment, entry, and subsequent RNA synthesis confirmed that MxA is able to target immediate early RNA synthesis of incoming RVFV particles. Thus, our reverse genetics systems are useful for dissecting individual steps of RVFV infection under non-BSL3 conditions.
- Published
- 2009
- Full Text
- View/download PDF
21. The cytoplasmic tails of Uukuniemi Virus (Bunyaviridae) G(N) and G(C) glycoproteins are important for intracellular targeting and the budding of virus-like particles.
- Author
-
Overby AK, Popov VL, Pettersson RF, and Neve EP
- Subjects
- Bunyaviridae, Cytoplasm, Viral Envelope Proteins physiology, Glycoproteins physiology, Uukuniemi virus chemistry, Uukuniemi virus physiology, Viral Proteins physiology, Virion physiology
- Abstract
Functional motifs within the cytoplasmic tails of the two glycoproteins G(N) and G(C) of Uukuniemi virus (UUK) (Bunyaviridae family) were identified with the help of our recently developed virus-like particle (VLP) system for UUK virus (A. K. Overby, V. Popov, E. P. Neve, and R. F. Pettersson, J. Virol. 80:10428-10435, 2006). We previously reported that information necessary for the packaging of ribonucleoproteins into VLPs is located within the G(N) cytoplasmic tail (A. K. Overby, R. F. Pettersson, and E. P. Neve, J. Virol. 81:3198-3205, 2007). The G(N) glycoprotein cytoplasmic tail specifically interacts with the ribonucleoproteins and is critical for genome packaging. In addition, two other regions in the G(N) cytoplasmic tail, encompassing residues 21 to 25 and 46 to 50, were shown to be important for particle generation and release. By the introduction of point mutations within these two regions, we demonstrate that leucines at positions 23 and 24 are crucial for the initiation of VLP budding, while leucine 46, glutamate 47, and leucine 50 are important for efficient exit from the endoplasmic reticulum and subsequent transport to the Golgi complex. We found that budding and particle generation are highly dependent on the intracellular localization of both glycoproteins. The short cytoplasmic tail of UUK G(C) contains a lysine at position -3 from the C terminus that is highly conserved among members of the Phlebovirus, Hantavirus, and Orthobunyavirus genera. Mutating this single amino acid residue in G(C) resulted in the mislocalization of not only G(C) but also G(N) to the plasma membrane, and VLP generation was compromised in cells expressing this mutant. Together, these results demonstrate that the cytoplasmic tails of both G(N) and G(C) contain specific information necessary for efficient virus particle generation.
- Published
- 2007
- Full Text
- View/download PDF
22. The glycoprotein cytoplasmic tail of Uukuniemi virus (Bunyaviridae) interacts with ribonucleoproteins and is critical for genome packaging.
- Author
-
Overby AK, Pettersson RF, and Neve EP
- Subjects
- Alanine genetics, Alanine metabolism, Amino Acid Sequence, Animals, Cell Line, Cricetinae, Genes, Reporter genetics, Glycoproteins chemistry, Glycoproteins genetics, Microscopy, Electron, Transmission, Molecular Sequence Data, Mutation genetics, Nucleoproteins genetics, Nucleoproteins metabolism, Protein Binding, Uukuniemi virus ultrastructure, Virion genetics, Virion metabolism, Virion ultrastructure, Cytoplasm metabolism, Genome, Viral genetics, Glycoproteins metabolism, Ribonucleoproteins metabolism, Uukuniemi virus genetics, Uukuniemi virus metabolism, Virus Assembly
- Abstract
We have analyzed the importance of specific amino acids in the cytoplasmic tail of the glycoprotein G(N) for packaging of ribonucleoproteins (RNPs) into virus-like particles (VLPs) of Uukuniemi virus (UUK virus), a member of the Bunyaviridae family. In order to study packaging, we added the G(N)/G(C) glycoprotein precursor (p110) to a polymerase I-driven minigenome rescue system to generate VLPs that are released into the supernatant. These particles can infect new cells, and reporter gene expression can be detected. To determine the role of UUK virus glycoproteins in RNP packaging, we performed an alanine scan of the glycoprotein G(N) cytoplasmic tail (amino acids 1 to 81). First, we discovered three regions in the tail (amino acids 21 to 25, 46 to 50, and 71 to 81) which are important for minigenome transfer by VLPs. Further mutational analysis identified four amino acids that were important for RNP packaging. These amino acids are essential for the binding of nucleoproteins and RNPs to the glycoprotein without affecting the morphology of the particles. No segment-specific interactions between the RNA and the cytoplasmic tail could be observed. We propose that VLP systems are useful tools for analyzing protein-protein interactions important for packaging of viral genome segments, assembly, and budding of other members of the Bunyaviridae family.
- Published
- 2007
- Full Text
- View/download PDF
23. Generation and analysis of infectious virus-like particles of uukuniemi virus (bunyaviridae): a useful system for studying bunyaviral packaging and budding.
- Author
-
Overby AK, Popov V, Neve EP, and Pettersson RF
- Subjects
- Animals, Bunyaviridae Infections virology, Cell Line, Cricetinae, Genome, Viral, Golgi Apparatus ultrastructure, Golgi Apparatus virology, Microscopy, Electron, Neutralization Tests, Transfection, Uukuniemi virus genetics, Uukuniemi virus pathogenicity, Uukuniemi virus ultrastructure, Virion genetics, Virion pathogenicity, Virion physiology, Virion ultrastructure, Virus Assembly, Uukuniemi virus physiology
- Abstract
In the present report we describe an infectious virus-like particle (VLP) system for the Uukuniemi (UUK) virus, a member of the Bunyaviridae family. It utilizes our recently developed reverse genetic system based on the RNA polymerase I minigenome system for UUK virus used to study replication, encapsidation, and transcription by monitoring reporter gene expression. Here, we have added the glycoprotein precursor expression plasmid together with the minigenome, nucleoprotein, and polymerase to generate VLPs, which incorporate the minigenome and are released into the supernatant. The particles are able to infect new cells, and reporter gene expression can be monitored if the trans-acting viral proteins (RNA polymerase and nucleoprotein) are also expressed in these cells. No minigenome transfer occurred in the absence of glycoproteins, demonstrating that the glycoproteins are absolutely required for the generation of infectious particles. Moreover, expression of glycoproteins alone was sufficient to produce and release VLPs. We show that the ribonucleoproteins (RNPs) are incorporated into VLPs but are not required for the generation of particles. Morphological analysis of the particles by electron microscopy revealed that VLPs, either with or without minigenomes, display a surface morphology indistinguishable from that of the authentic UUK virus and that they bud into Golgi vesicles in the same way as UUK virus does. This infectious VLP system will be very useful for studying the bunyaviral structural components required for budding and packaging of RNPs and receptor binding and may also be useful for the development of new vaccines for the human pathogens from this family.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.